Sort
17,288 grants matching “multiple sclerosis”
Obesity as a Driver of Inflammation and Brain Volume Loss in Pediatric Multiple Sclerosis
$194,210James Nicholas Brenton · University Of Virginia · K23 · FY2024 · NS
Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis
$194,184Esther Melamed · University Of Texas At Austin · K08 · FY2023 · AA
Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis
$194,184Esther Melamed · University Of Texas At Austin · K08 · FY2020 · AA
Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis
$194,184Esther Melamed · University Of Texas At Austin · K08 · FY2021 · AA
Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis
$194,184Esther Melamed · University Of Texas At Austin · K08 · FY2024 · AA
Alcohol's Impact on the Gut-Brain Axis in a Mouse Model of Multiple Sclerosis
$194,184Esther Melamed · University Of Texas At Austin · K08 · FY2022 · AA
The role of sulfatide in myelin stability
$194,063Jeffrey L. Dupree · Virginia Commonwealth University · R21 · FY2021 · NS
Grey Matter of Lesions and Neurodegeration in Multiple Sclerosis on 7-Telsa MRI
$194,039Daniel M Harrison · Johns Hopkins University · K23 · FY2014 · NS
A new biomarker for frontotemporal lobar degeneration with TDP-43 proteinopathy and Alzheimer's disease
$194,030Qinwen Mao · University Of Utah · R21 · FY2024 · AG
Role of HLA class II genes in demyelination
$194,006Chella S David · Mayo Clinic Rochester · R01 · FY2008 · NS
Role of HLA class II genes in demyelination
$194,006Chella S David · Mayo Clinic Rochester · R01 · FY2007 · NS
Role of HLA class II genes in demyelination
$194,006Chella S David · Mayo Clinic Rochester · R01 · FY2009 · NS
Signaling pathways controlling myelination
$193,986Wendy B Macklin · University Of Colorado Denver · R01 · FY2009 · NS
SAFETY AND EFFICACY OF TWO DOSES OF BETASERON
$193,916Ohio State University · M01 · FY2001 · RR
EVALUATE EFFICACY OF AVONEX &SECONDARY MULTIPLE SCLEROSIS
$193,916Ohio State University · M01 · FY2001 · RR
PHASE 2 STUDY OF HU23F2G IN ACUTE EXACERBATIONS OF MULTIPLE SCLEROSIS
$193,916Ohio State University · M01 · FY2001 · RR
AVONEX IN TREATING HIGH DEVELOPMENT OF MULTIPLE SCLEROSIS
$193,916Ohio State University · M01 · FY2001 · RR
Core B: Mass spectrometry, proteomics, metabolomics and lipidomics
$193,824John M Asara · Brigham And Women'S Hospital · P01 · FY2018 · CA
Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers
$193,783Andrew J Solomon · University Of Vermont & St Agric College · K02 · FY2019 · NS
Improving Diagnosis of Multiple Sclerosis Through the Integration of Novel Imaging and Laboratory Biomarkers
$193,783Andrew J Solomon · University Of Vermont & St Agric College · K02 · FY2020 · NS
Structure Determination of the Chemokine Receptor CCR2 with Novel Inhibitors
$193,750Tracy M Handel · University Of California, San Diego · R21 · FY2017 · AI
Investigation of Novel Roles For IRF7 in EAE
$193,750David N Irani · University Of Michigan At Ann Arbor · R21 · FY2017 · NS
Identification of TSC cellular phenotypes using patient-derived iPSCs
$193,750Gabriella D'arcangelo · Rutgers, The State Univ Of N.J. · R21 · FY2015 · NS
Toward a CRISPR-AAV Gene Therapy Targeting a Mitochondrial Anchor to Treat Progressive Multiple Sclerosis
$193,750Shing Yan Chiu · University Of Wisconsin-Madison · R21 · FY2020 · NS
Development of a conceptual model of subjective physical and mental fatigability: the MI-FI study
$193,750Anna Louise Kratz · University Of Michigan At Ann Arbor · R21 · FY2017 · AG